The Incretin Effect: Why Food Boosts Insulin More
GLP-1 and GIP: The Two Incretins
50–70%
Share of postprandial insulin secretion driven by the incretin effect in healthy humans, according to isoglycemic clamp studies.
Nauck et al., Diabetes Obes Metab, 2018
Nauck et al., Diabetes Obes Metab, 2018
View as imageIf you inject glucose directly into a vein, your pancreas releases a certain amount of insulin. If you swallow the same amount of glucose and let it travel through your gut, your pancreas releases two to three times more insulin, even though blood sugar levels end up the same.[1] This gap between oral and intravenous insulin responses is called the incretin effect, and it is one of the most important concepts in metabolic biology. It explains how your gut communicates with your pancreas, why type 2 diabetes disrupts blood sugar control, and how an entire class of blockbuster drugs came to exist.
Key Takeaways
- The incretin effect produces a 2-3x greater insulin response to oral glucose compared to intravenous glucose at identical blood sugar levels (Nauck and Meier, 2018)
- Two gut peptides drive the effect: GIP accounts for approximately 45% of meal-stimulated insulin, GLP-1 for about 29%, and glucose alone for just 26% (Seino et al., 2010)
- Both GIP and GLP-1 work through G-protein coupled receptors that raise intracellular cAMP, triggering insulin granule release only when blood glucose is elevated (Baggio and Drucker, 2007)
- In type 2 diabetes, the incretin effect is severely diminished or absent, primarily because GIP loses its ability to stimulate insulin secretion from beta cells (Nauck et al., 2021)
- GLP-1's insulinotropic action remains largely intact in type 2 diabetes, which is why GLP-1 receptor agonists like semaglutide and liraglutide lower blood sugar effectively (Nauck et al., 2021)
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown superior glucose-lowering and weight loss compared to GLP-1-only drugs, reigniting scientific interest in GIP biology (Del Prato et al., 2022)
What is the incretin effect?
The term "incretin" comes from "intestine secretion insulin." It refers to hormones released by the gut after eating that amplify glucose-stimulated insulin secretion from pancreatic beta cells.[2]
The incretin effect is measured using a technique called the isoglycemic clamp. Researchers give a subject an oral glucose load and record both their blood sugar curve and their insulin response. On a separate day, they infuse glucose intravenously at whatever rate is needed to perfectly replicate that same blood sugar curve. The difference in insulin output between the two conditions is the incretin effect.[1]
In healthy people, this difference is large. Oral glucose elicits a two- to threefold higher insulin secretory response compared to intravenous glucose that produces identical plasma glucose concentrations.[1] That means glucose alone, acting directly on beta cells, is responsible for less than half of the insulin your body releases after a meal. The rest depends on signals from the gut.
The two incretin hormones: GIP and GLP-1
Two peptide hormones account for the incretin effect. Glucose-dependent insulinotropic polypeptide (GIP) is secreted by K cells concentrated in the duodenum and jejunum. Glucagon-like peptide-1 (GLP-1) is secreted by L cells distributed throughout the lower small intestine and colon.[2]
Both are released within minutes of nutrient ingestion. Both fat and carbohydrate stimulate GIP secretion. GLP-1 secretion responds to carbohydrate, fat, and protein arriving in the lower gut.[3]
The individual contributions to postprandial insulin secretion have been quantified: GIP accounts for approximately 45%, GLP-1 for about 29%, and glucose itself for roughly 26%.[3] GIP is the quantitatively dominant incretin. GLP-1 contributes less to the raw insulin signal but exerts powerful glucoregulatory effects through other mechanisms, including suppression of glucagon secretion from alpha cells and slowing of gastric emptying.[1]
Both hormones are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). The half-life of intact, biologically active GIP is about 7 minutes. For GLP-1, it is roughly 2 minutes.[2] This rapid degradation means incretin action is tightly time-limited. It also explains why DPP-4 inhibitors became one of the first incretin-based drug classes.
How the incretin effect was discovered
Scientists suspected the gut influenced insulin secretion as far back as 1902, when Bayliss and Starling demonstrated that the intestine released factors that stimulated the pancreas.[4] But formal proof of the incretin effect did not arrive until the 1960s, when researchers showed that plasma insulin levels following oral glucose were consistently higher than those observed after intravenous glucose at the same blood sugar concentrations.
In 1971, John Brown isolated GIP from porcine intestine, a 42-amino-acid peptide originally named "gastric inhibitory polypeptide" for its ability to suppress gastric acid secretion. Two years later, Brown and John Dupre demonstrated that GIP potentiated glucose-stimulated insulin secretion in humans, establishing it as the first confirmed incretin hormone.[4]
GLP-1 arrived later. In 1987, laboratories led by Habener and Holst independently identified GLP-1 as a regulator of insulin secretion. GLP-1 turned out to be derived from the same proglucagon gene that produces glucagon itself, but processed differently in intestinal L cells versus pancreatic alpha cells.[2]
Together, GIP and GLP-1 accounted for the full incretin effect. Blocking both receptors simultaneously in healthy subjects abolishes the difference between oral and intravenous insulin responses.[5]
How incretins amplify insulin secretion at the molecular level
GIP and GLP-1 bind to their specific receptors (GIPR and GLP-1R), both members of the G-protein coupled receptor family expressed on pancreatic beta cells.[3]
Receptor activation triggers a signaling cascade:
- cAMP rises. Incretin receptor binding activates adenylate cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations.
- PKA and EPAC2 activate. Elevated cAMP activates protein kinase A (PKA) and exchange protein activated by cAMP2 (EPAC2), two downstream effectors.
- Calcium influx increases. These effectors alter ion channel activity, raising cytosolic calcium levels.
- Insulin granules fuse with the membrane. Higher calcium triggers exocytosis of insulin-containing granules.[3]
The critical feature of this pathway is glucose dependence. The cAMP signal from incretins only amplifies insulin release when blood glucose is already elevated enough to initiate beta cell depolarization on its own.[2] When blood sugar drops to normal or low levels, the incretin signal has minimal effect. This built-in safety mechanism means incretins boost insulin when it is needed and stay quiet when it is not.
Beyond acute insulin secretion, both GIP and GLP-1 promote beta cell proliferation and inhibit apoptosis, expanding beta cell mass over time.[2] These trophic effects are part of why incretin biology matters for long-term glucose homeostasis, not just the immediate postprandial period.
What happens to the incretin effect in type 2 diabetes
In people with type 2 diabetes, the incretin effect is severely diminished or completely absent.[1] This was first demonstrated by Michael Nauck and colleagues using isoglycemic clamp studies comparing diabetic patients with healthy controls. Where healthy subjects showed a two- to threefold amplification of insulin from oral versus intravenous glucose, diabetic subjects showed little to no difference.
The loss of the incretin effect in type 2 diabetes is not primarily a secretion problem. GIP and GLP-1 are released from the gut in roughly normal or only mildly reduced amounts in most people with type 2 diabetes.[1] The problem lies downstream, at the level of the pancreatic beta cell response.
GIP is the bigger casualty. GIP loses much of its acute insulinotropic activity in the diabetic endocrine pancreas, for reasons that remain largely unknown.[5] The GIP receptor is still expressed on beta cells, but the signal it produces fails to translate into proportional insulin release. Proposed explanations include receptor downregulation, impaired post-receptor signaling, or the toxic effects of chronic hyperglycemia on the beta cell's ability to respond to GIP.
GLP-1 tells a different story. Its insulinotropic effects are only slightly impaired in type 2 diabetes.[5] At pharmacological doses, GLP-1 receptor stimulation still lowers blood glucose in diabetic patients. This preserved responsiveness is the entire biological foundation for GLP-1 receptor agonist drugs.
There is an important nuance here, though. Even in healthy people, GLP-1's physiological contribution to the incretin effect is relatively small compared to GIP's. GLP-1's main glucoregulatory role operates through glucagon suppression, appetite reduction, and slowed gastric emptying rather than direct insulin amplification.[1]
GIP and GLP-1 beyond insulin: divergent roles
While both incretins share the core function of amplifying insulin secretion, their actions diverge in several tissues:
Glucagon. GLP-1 suppresses glucagon secretion from alpha cells during hyperglycemia, helping to lower blood sugar. GIP does the opposite during hypoglycemia: it stimulates glucagon release, helping to raise blood sugar back to normal. Both effects are glucose-dependent.[5]
Adipose tissue. GIP promotes fat deposition in white adipose tissue through direct interaction with GIP receptors on adipocytes and through stimulation of regional blood flow. GLP-1 does not have this effect.[5]
Bone. GIP promotes bone formation by stimulating osteoblast activity. GLP-1 inhibits bone resorption. Both may contribute to the post-meal suppression of bone turnover.[3]
Appetite and body weight. GLP-1 at pharmacological concentrations reduces appetite, food intake, and long-term body weight. GIP's role in appetite is less clear. Animal studies suggest GIP may also reduce food intake, but human data has not confirmed this.[5]
Cardiovascular system. GLP-1 receptor agonists have demonstrated cardiovascular event reduction in large clinical trials. GIP and GLP-1 receptors are both expressed in the heart and vasculature, though the clinical significance of GIP's cardiovascular actions is less established.[4]
From incretin biology to incretin-based drugs
The preserved GLP-1 responsiveness in type 2 diabetes launched an entire pharmaceutical category. GLP-1 receptor agonists, engineered to resist DPP-4 degradation, lower blood sugar and reduce body weight by mimicking and amplifying the natural GLP-1 signal. Exenatide, derived from a peptide in Gila monster venom, was the first approved in 2005. Semaglutide and liraglutide followed, with longer half-lives and stronger clinical effects.[6]
DPP-4 inhibitors took a different approach: rather than mimicking incretins, they block the enzyme that destroys them. Sitagliptin, vildagliptin, and saxagliptin extend the lifespan of both endogenous GIP and GLP-1.[2] Their glucose-lowering effect is more modest than GLP-1 receptor agonists, partly because they amplify both GIP and GLP-1 at physiological rather than pharmacological levels, and partly because GIP's effectiveness is already compromised in the diabetic beta cell.
The most recent development is dual and triple receptor agonism. Tirzepatide, a single molecule that activates both GIP and GLP-1 receptors, has demonstrated superior glycemic control and weight loss compared to selective GLP-1 receptor agonists in clinical trials.[7] This was unexpected. If GIP signaling is impaired in diabetes, why would adding a GIP agonist to a GLP-1 agonist improve outcomes?
Several hypotheses are being tested. Pharmacological doses of a GIP agonist may overcome receptor resistance. The GIP component may contribute primarily through non-pancreatic effects on adipose tissue and appetite circuits. Or the interaction between GIP and GLP-1 receptor signaling may produce synergistic effects that neither pathway achieves alone.[7] Research into triple agonists targeting GLP-1, GIP, and glucagon receptors simultaneously is now underway, with compounds like retatrutide in advanced clinical trials.
Open questions and evidence gaps
The incretin effect is well-established as a physiological phenomenon, but several questions remain unresolved.
The mechanism behind GIP resistance in type 2 diabetes is still unclear. Whether it is a cause or consequence of chronic hyperglycemia is debated. Some evidence suggests that restoring normoglycemia partially restores GIP responsiveness, but the data is inconsistent.[5]
Local production of GIP and GLP-1 within the pancreatic islets themselves (rather than in the gut) has been observed in alpha cells.[5] What role this paracrine incretin signaling plays, and whether it is altered in diabetes, is an active area of investigation.
The incretin effect after bariatric surgery is another frontier. Roux-en-Y gastric bypass dramatically increases GLP-1 secretion by delivering nutrients to L cell-rich regions of the small intestine more rapidly. This exaggerated incretin response may partially explain the rapid diabetes remission observed after surgery, though the evidence is not conclusive.[1]
Whether GIP agonism or GIP antagonism is the optimal therapeutic strategy for obesity remains an open debate. Tirzepatide's success as a GIP/GLP-1 dual agonist has challenged the earlier assumption that GIP's fat-storing properties made it an undesirable drug target.[7]
The Bottom Line
The incretin effect is the two- to threefold amplification of insulin secretion that occurs when glucose arrives through the gut rather than the bloodstream. Two peptide hormones, GIP and GLP-1, drive this amplification through glucose-dependent cAMP signaling in pancreatic beta cells. In type 2 diabetes, the incretin effect is lost primarily because GIP's signal fails at the beta cell level, while GLP-1 retains most of its activity. This selective preservation of GLP-1 function is why GLP-1 receptor agonists work as diabetes and obesity drugs, and the recent success of dual GIP/GLP-1 agonists like tirzepatide has reopened fundamental questions about how these two incretin pathways interact.